New schizophrenia shot could offer cheaper alternative to Brand-Name drug

NCT ID NCT07493551

Recruiting now Disease control Sponsor: CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new generic version of a 3-month schizophrenia injection works the same as the brand-name drug Invega Trinza. About 260 Chinese adults with stable schizophrenia will receive multiple doses of either the test or reference drug. The goal is to see if the two formulations reach similar drug levels in the blood and have similar safety profiles.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paliperidone palmitate injection (3-month formulation)
What this could lead to: If successful, this could provide a more affordable, equally effective long-acting treatment option for schizophrenia patients in China.
What could go wrong: This is a bioequivalence study, not a test of new efficacy or safety. It only compares two formulations in a specific population, so results may not apply broadly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Beijing Anding Hospital Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100120, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.